10-Q: Medifast Reports Significant Revenue Drop, Increased Losses

Medifast, Inc. announced a substantial decline in revenue and a widening net loss for the second quarter of 2026, primarily driven by a significant decrease in active coaches.

Summary

• Medifast reported a net loss of $3.1 million ($0.28 per diluted share) for the three months ended June 30, 2026, a significant downturn from a net income of $2.5 million ($0.22 per diluted share) in the same period of 2025.
• For the six months ended June 30, 2026, the net loss was $5.2 million ($0.47 per diluted share), compared to a net income of $1.7 million ($0.15 per diluted share) in the prior year.
• Revenue for the second quarter of 2026 decreased by 27.6% to $76.4 million, down from $105.6 million in the second quarter of 2025.
• The decrease in revenue is attributed to a significant drop in active earning coaches, falling to approximately 11,700 in Q2 2026 from 22,800 in Q2 2025.
• The company is undergoing a strategic transformation, rebranding its OPTAVIA business to Trilivy, focusing on a broader metabolic health market.
• Despite the financial challenges, the average revenue per active earning coach increased by 41.0% to $6,529 in Q2 2026 compared to $4,630 in Q2 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue and profit declines, increased operating losses, and a substantial decrease in active coaches, despite strategic rebranding efforts.

Positives

• Average revenue per active earning coach increased by 41.0% to $6,529 for the three months ended June 30, 2026, indicating improved productivity among remaining coaches.
• The company is strategically rebranding its OPTAVIA business to Trilivy, aiming to address the broader metabolic health market.
• Medifast launched the Medifast Metabolic Health Institute to advance metabolic health through research and education.
• The company has a well-capitalized business with a strong balance sheet, showing total assets of $260.4 million as of June 30, 2026.

Negatives

• Net loss for the three months ended June 30, 2026, was $3.1 million, a significant increase from a net income of $2.5 million in the prior year.
• Revenue for the three months ended June 30, 2026, decreased by 27.6% to $76.4 million compared to $105.6 million in the prior year.
• The number of active earning coaches decreased significantly to approximately 11,700 in Q2 2026 from 22,800 in Q2 2025.
• Loss from operations for the three months ended June 30, 2026, was $4.3 million, compared to a loss of $1.1 million in the prior year.
• Gross profit margin decreased to 69.9% in Q2 2026 from 72.6% in Q2 2025, primarily due to loss of leverage on fixed costs.
• Selling, general, and administrative (SG&A) expenses as a percentage of revenue increased to 75.6% in Q2 2026 from 73.6% in Q2 2025.

Risks

• Continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid and continued adoption of GLP-1 medications for weight loss.
• The company expects the number of active earning coaches to continue to decline in 2026.
• Macroeconomic uncertainty and volatility in markets where the company, its suppliers, and its independent coaches operate, including the impact of inflation and tariffs.
• Increased competition in the metabolic health and weight loss industry, including from GLP-1 medications and other direct-selling organizations.
• Potential for adverse effects on results of operations, financial position, or liquidity from the unfavorable resolution of legal actions, although the company does not believe current proceedings will have a material adverse effect.

Future Outlook

The company expects the number of active earning coaches to continue to decline in 2026. Medifast is focusing on improving coach productivity and expanding its coach network as part of its long-term growth strategy in the broader metabolic health market. The company expects upcoming innovations in its product line to further strengthen its offerings.

Management Comments

• The transition from OPTAVIA to a new brand with the launch of Trilivy represents an evolution of the company's vision, platform, and purpose, expanding beyond traditional weight loss to address the broader metabolic health challenges impacting more than 90% of U.S. adults today.
• This strategic shift targets a larger and what is believed to be a more sustainable market, focusing on a long-term growth strategy intended to guide the Company over the next decade by aligning science, products, and coaching with increasing demand for new solutions as awareness of metabolic dysfunction grows.
• We believe our coach-based model is scalable, drives both client success and growth, and represents a key competitive advantage.
• We expect that simplifying the fundamentals of our products and programs, and also the way we talk about them, will increase client acquisition and the conversion of clients into new coaches.
• Medifast continues to invest strategically in tools, programs, and educational resources to support our coaches - the Company's most effective client acquisition engine.

Industry Context

StockSavvy.ai notes that Medifast's strategic pivot to 'Trilivy' and a broader 'metabolic health' focus aligns with a growing industry trend recognizing that weight management and overall wellness extend beyond simple calorie restriction. The increasing prevalence and effectiveness of GLP-1 medications are a significant competitive factor, pushing companies like Medifast to emphasize holistic lifestyle changes, behavioral support, and scientific backing as differentiators.

Comparison to Industry Standards

• The company's revenue decline of 27.6% in Q2 2026 and 31.1% year-to-date is a significant underperformance compared to the broader health and wellness sector, which has seen varied growth depending on specific niches.
• The substantial decrease in active coaches (from 22,800 to 11,700) is a critical concern, as direct selling models heavily rely on network size and activity. Competitors in the direct selling space, such as Herbalife or Nu Skin, often focus on maintaining or growing their distributor networks through robust training and incentive programs.
• The increase in average revenue per coach (41.0%) suggests a potential shift towards higher-performing coaches, a strategy that some direct selling companies employ to optimize their sales force, though it comes at the cost of overall network size.
• The company's focus on 'metabolic health' and the launch of the Medifast Metabolic Health Institute positions it against other health-focused companies and pharmaceutical interventions (like GLP-1s) that are increasingly entering the wellness space. Companies like WeightWatchers have also evolved their offerings to include broader health and wellness solutions beyond just weight loss.
• The competitive landscape includes pharmaceutical companies developing weight loss drugs (e.g., Novo Nordisk with Ozempic/Wegovy, Eli Lilly with Mounjaro/Zepbound), which are gaining significant market share and influencing consumer perceptions of weight management.

Legal Proceedings

• The company is subject to various litigation and similar proceedings arising from the ordinary course of business. Management does not believe these proceedings will have a material adverse effect, but acknowledges that results cannot be predicted with certainty.

Stakeholder Impact

• Shareholders: Negative impact due to significant decline in revenue, increased operating losses, and a substantial decrease in active coaches, leading to a lower share price.
• Employees: Potential impact from cost-saving measures or restructuring due to financial performance, though specific details are not provided.
• Coaches: Significant impact from the decline in active coaches and the company's strategic shift, with a focus on 'productive coaches' potentially leading to fewer overall opportunities.
• Customers: May experience changes in product offerings and support as the company transitions to the 'Trilivy' brand and broader metabolic health focus.

Next Steps

• Continue strategic transformation and execution of the focus on holistic metabolic health.
• Improve coach productivity and expand the coach network.
• Bring the updated Trilivy Reset Fueling product line fully to market in the current quarter.
• Advance metabolic health through rigorous research and credible, evidence-based education via the Medifast Metabolic Health Institute.
• Continue to monitor macroeconomic conditions and adapt business operations as necessary.
• Evaluate potential acquisitions that complement the business.

Key Dates

Recommendation

The filing indicates a significant deterioration in financial performance, characterized by a sharp decline in revenue, widening operating losses, and a substantial reduction in the active coach network. While the company is undertaking a strategic rebranding and focusing on metabolic health, the current financial trends and competitive pressures, particularly from GLP-1 medications, suggest a challenging near-to-medium term outlook. The increased revenue per coach is a positive but does not offset the overall decline in business activity. Therefore, a sell recommendation is warranted based on these negative indicators.

Keywords

Metabolic Health, Weight Loss, Trilivy, OPTAVIA, Coach Network, GLP-1 Medications, Financial Results, Revenue Decline